Last 12 months
Inside the activity.
0 purchase rows · 40 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 15 |
| Jul 2026 | 0 | 6 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 3 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 18,571 | $0.00 Strike: $43.24 | $0.00 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · derivative · entry 10 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,289 Underlying: Common Stock · 18,571 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Option granted February 06, 2017 and vests monthly over four years. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 9,094 | $0.00 Strike: $35.99 | $0.00 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · derivative · entry 9 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,094 shares Expires 2026-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted February 05, 2016 and vested monthly over four years. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 18,057 | $114.94 | $2,075,549.23 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 8 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
Exercise / conversionCommon Stock | 18,057 | $81.05 | $1,463,519.85 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 7 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,690 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 15,833 | $114.94 | $1,819,913.10 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 6 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
Exercise / conversionCommon Stock | 15,833 | $81.49 | $1,290,231.17 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 5 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 18,571 | $114.94 | $2,134,630.60 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 4 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
Exercise / conversionCommon Stock | 18,571 | $43.24 | $803,010.04 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 3 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 9,094 | $114.94 | $1,045,303.46 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 2 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $112.43 to $117.58. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 12, 2020 Filed May 15, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
Exercise / conversionCommon Stock | 9,094 | $35.99 | $327,293.06 |
DisclosureSEC source: 0001209191-20-029401 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:17 UTC |
ABERNETHY MATTChief Financial Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 15,000 | $73.60 Strike: $73.60 | $1,104,000.00 |
DisclosureSEC source: 0001209191-20-028394 · doc4.xml · derivative · entry 3 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 15,000 shares Expires 2027-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Option granted December 1, 2017 and vested at 25% upon first anniversary (December 1, 2018) and remaining 75% vesting in 36 equal monthly installments beginning November 1, 2018. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:17 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 15,000 | $110.21 | $1,653,133.50 |
DisclosureSEC source: 0001209191-20-028394 · doc4.xml · nonDerivative · entry 2 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,953 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $110.00 to $110.95. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:17 UTC |
ABERNETHY MATTChief Financial Officer
|
Exercise / conversionCommon Stock | 15,000 | $73.60 | $1,104,000.00 |
DisclosureSEC source: 0001209191-20-028394 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,953 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 07, 2020 Filed May 12, 2020 00:06 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 8,682 | $105.44 | $915,454.39 |
DisclosureSEC source: 0001209191-20-028392 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,741 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $105.00 to $106.20. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 20:27 UTC |
SHERWIN STEPHEN ADirector
|
SaleCommon Stock | 17,687 | $99.39 | $1,757,965.76 |
DisclosureSEC source: 0001209191-20-026306 · doc4.xml · nonDerivative · entry 1 SHERWIN STEPHEN A · CIK 0001079462 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,861 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.34 to $102.34. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 28, 2020 Filed Apr 30, 2020 20:25 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 1,741 | $102.49 | $178,435.09 |
DisclosureSEC source: 0001209191-20-026302 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,953 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:32 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 1,934 | $99.52 | $192,466.85 |
DisclosureSEC source: 0001209191-20-026062 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,694 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 252 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:46 UTC |
ROBERTS EIRYChief Medical Officer
|
SaleCommon Stock | 1,934 | $99.47 | $192,376.33 |
DisclosureSEC source: 0001209191-20-026072 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,416 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.63 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 223 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:44 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 1,934 | $99.45 | $192,329.14 |
DisclosureSEC source: 0001209191-20-026071 · doc4.xml · nonDerivative · entry 1 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,941 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.59 to $101.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:43 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,934 | $99.49 | $192,415.98 |
DisclosureSEC source: 0001209191-20-026070 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,021 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 156 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:42 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,934 | $99.41 | $192,258.17 |
DisclosureSEC source: 0001209191-20-026069 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 113,423 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:41 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 2,906 | $99.45 | $289,015.65 |
DisclosureSEC source: 0001209191-20-026068 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,971 F1 · kind: Sale of 2,906 shares of common stock issued upon vesting of 5,520 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (2,614) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:40 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,934 | $99.47 | $192,376.72 |
DisclosureSEC source: 0001209191-20-026066 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,967 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.65 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 251 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:38 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 1,934 | $99.46 | $192,363.57 |
DisclosureSEC source: 0001209191-20-026065 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,631 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.65 to $101.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 247 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:35 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,934 | $99.46 | $192,351.19 |
DisclosureSEC source: 0001209191-20-026064 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,633 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.65 to $101.11. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 251 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| April 24, 2020 Filed Apr 29, 2020 00:33 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 1,934 | $99.45 | $192,337.85 |
DisclosureSEC source: 0001209191-20-026063 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,344 F1 · kind: Sale of 1,934 shares of common stock issued upon vesting of 3,675 performance restricted stock units on April 24, 2020 to cover withholding taxes, with the balance of the shares (1,741) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $97.56 to $101.13. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 15, 2020 Filed Apr 18, 2020 01:48 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 8,632 | $94.65 | $817,017.94 |
DisclosureSEC source: 0001209191-20-025028 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,603 F1 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $92.80 to $95.63. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. F3 · balance_after: Includes 148 shares acquired under the Neurocrine Biosciences 2018 Employee Stock Purchase Plan on February 28, 2020. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:21 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
Exercise / conversionNon-Qualified Stock Option · Derivative | 15,927 | $0.00 Strike: $81.49 | $0.00 |
DisclosureSEC source: 0001209191-20-008513 · doc4.xml · derivative · entry 7 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,596 Underlying: Common Stock · 15,927 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Option granted February 5, 2018 and vests monthly over four years. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:21 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
Exercise / conversionIncentive Stock Option · Derivative | 13,042 | $0.00 Strike: $32.99 | $0.00 |
DisclosureSEC source: 0001209191-20-008513 · doc4.xml · derivative · entry 6 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,042 shares Expires 2025-02-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Option granted February 3, 2015 and vested monthly over four years. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:21 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 15,927 | $104.56 | $1,665,374.90 |
DisclosureSEC source: 0001209191-20-008513 · doc4.xml · nonDerivative · entry 5 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F5 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.56 to $105.08. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:21 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
Exercise / conversionCommon Stock | 15,927 | $81.49 | $1,297,891.23 |
DisclosureSEC source: 0001209191-20-008513 · doc4.xml · nonDerivative · entry 4 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:21 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 13,042 | $104.56 | $1,363,710.65 |
DisclosureSEC source: 0001209191-20-008513 · doc4.xml · nonDerivative · entry 3 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F3 · kind: The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F4 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $104.00 to $104.56. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 00:21 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
Exercise / conversionCommon Stock | 13,042 | $32.99 | $430,255.58 |
DisclosureSEC source: 0001209191-20-008513 · doc4.xml · nonDerivative · entry 2 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,242 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:21 UTC |
Lloyd-Smith MalcolmChief Regulatory Officer
|
SaleCommon Stock | 1,015 | $103.28 | $104,826.56 |
DisclosureSEC source: 0001209191-20-008513 · doc4.xml · nonDerivative · entry 1 Lloyd-Smith Malcolm · CIK 0001557146 · Chief Regulatory Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,200 F1 · kind: Sale of 1,015 shares of common stock issued upon vesting of 1,928 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (913) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:23 UTC |
ROBERTS EIRYChief Medical Officer
|
SaleCommon Stock | 1,623 | $103.31 | $167,675.38 |
DisclosureSEC source: 0001209191-20-008518 · doc4.xml · nonDerivative · entry 1 ROBERTS EIRY · CIK 0001727606 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,452 F1 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,084 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,461) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.22 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:17 UTC |
Lippoldt DarinChief Legal Officer
|
SaleCommon Stock | 1,522 | $103.32 | $157,247.10 |
DisclosureSEC source: 0001209191-20-008503 · doc4.xml · nonDerivative · entry 1 Lippoldt Darin · CIK 0001504783 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,124 F1 · kind: Sale of 1,522 shares of common stock issued upon vesting of 2,891 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,369) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:16 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
SaleCommon Stock | 1,218 | $103.31 | $125,832.55 |
DisclosureSEC source: 0001209191-20-008498 · doc4.xml · nonDerivative · entry 1 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,682 F1 · kind: Sale of 1,218 shares of common stock issued upon vesting of 2,313 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,095) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.23 to $104.14. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:14 UTC |
GORMAN KEVIN CHARLESDirector · Chief Executive Officer
|
SaleCommon Stock | 3,248 | $103.35 | $335,696.07 |
DisclosureSEC source: 0001209191-20-008494 · doc4.xml · nonDerivative · entry 1 GORMAN KEVIN CHARLES · CIK 0001201096 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,357 F1 · kind: Sale of 3,248 shares of common stock issued upon vesting of 6,169 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (2,921) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $101.985 to $104.12. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:10 UTC |
Cooke JulieChief Human Resources Officer
|
SaleCommon Stock | 913 | $103.26 | $94,276.20 |
DisclosureSEC source: 0001209191-20-008487 · doc4.xml · nonDerivative · entry 1 Cooke Julie · CIK 0001776977 · Chief Human Resources Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 F1 · kind: Sale of 913 shares of common stock issued upon vesting of 1,735 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (822) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.23 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:13 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,623 | $103.33 | $167,710.27 |
DisclosureSEC source: 0001209191-20-008491 · doc4.xml · nonDerivative · entry 1 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,975 F1 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,084 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,461) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 90 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.22 to $104.09. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:09 UTC |
Bozigian Haig P.Chief Development Officer
|
SaleCommon Stock | 1,623 | $103.33 | $167,701.67 |
DisclosureSEC source: 0001209191-20-008484 · doc4.xml · nonDerivative · entry 1 Bozigian Haig P. · CIK 0001423837 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,641 F1 · kind: Sale of 1,623 shares of common stock issued upon vesting of 3,084 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,461) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.23 to $104.10. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:08 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 2,030 | $103.32 | $209,747.31 |
DisclosureSEC source: 0001209191-20-008481 · doc4.xml · nonDerivative · entry 1 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,087 F1 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,855 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,825) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.05. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 07, 2020 Filed Feb 12, 2020 00:06 UTC |
ABERNETHY MATTChief Financial Officer
|
SaleCommon Stock | 2,030 | $103.35 | $209,806.59 |
DisclosureSEC source: 0001209191-20-008478 · doc4.xml · nonDerivative · entry 1 ABERNETHY MATT · CIK 0001724097 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,701 F1 · kind: Sale of 2,030 shares of common stock issued upon vesting of 3,855 restricted stock units on February 7, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,825) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F2 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $102.24 to $104.07. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:35 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantRestricted Stock Unit · Derivative | 9,719 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · derivative · entry 5 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,719 Underlying: Common Stock · 9,719 shares Expires not disclosed F9 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F10 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F10 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:35 UTC |
BENEVICH ERICChief Commercial Officer
|
GrantStock Option · Derivative | 61,347 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · derivative · entry 4 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,347 Underlying: Common Stock · 61,347 shares Expires 2030-02-06 F8 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and excercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:35 UTC |
BENEVICH ERICChief Commercial Officer
|
SaleCommon Stock | 1,395 | $101.48 | $141,560.83 |
DisclosureSEC source: 0001209191-20-007671 · doc4.xml · nonDerivative · entry 3 BENEVICH ERIC · CIK 0001643653 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,262 F6 · kind: Sale of 1,395 shares of common stock issued upon vesting of 2,650 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (1,255) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F7 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $100.12 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:54 UTC |
Gano KyleChief Business Development Off
|
GrantRestricted Stock Unit · Derivative | 12,148 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007695 · doc4.xml · derivative · entry 6 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,148 Underlying: Common Stock · 12,148 shares Expires not disclosed F11 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F12 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F12 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:54 UTC |
Gano KyleChief Business Development Off
|
GrantStock Option · Derivative | 76,683 | $0.00 Strike: $102.90 | $0.00 |
DisclosureSEC source: 0001209191-20-007695 · doc4.xml · derivative · entry 5 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,683 Underlying: Common Stock · 76,683 shares Expires 2030-02-06 F10 · derivative.exercise_date: Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 6, 2020 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:54 UTC |
Gano KyleChief Business Development Off
|
SaleCommon Stock | 1,000 | $101.41 | $101,413.00 |
DisclosureSEC source: 0001209191-20-007695 · doc4.xml · nonDerivative · entry 4 Gano Kyle · CIK 0001567160 · Chief Business Development Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,514 F8 · kind: Sale of 1,000 shares of common stock issued upon vesting of 1,900 restricted stock units on February 6, 2020 to cover payroll and withholding taxes, with the balance of the shares (900) maintained by the Reporting Person; the disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 2 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan. F9 · price: Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $99.73 to $103.01. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 06, 2020 Filed Feb 7, 2020 23:50 UTC |
Grigoriadis Dimitri E.Chief Research Officer
|
GrantRestricted Stock Unit · Derivative | 7,897 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007691 · doc4.xml · derivative · entry 5 Grigoriadis Dimitri E. · CIK 0001423838 · Chief Research Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,897 Underlying: Common Stock · 7,897 shares Expires not disclosed F8 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer Common Stock. F9 · derivative.exercise_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. F9 · derivative.expiration_date: The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 6, 2021, February 6, 2022, February 6, 2023, and February 6, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.